NCT02013193已完成不适用
Prospective, Randomized, Multicentre Clinical Study of the Hemoteq Ranger™ Paclitaxel-Coated PTA Balloon Catheter (Ranger DCB) in Comparison to Uncoated PTA Balloons in Femoropopliteal Lesions
Hemoteq AG22 个研究点 分布在 3 个国家目标入组 105 人开始时间: 2014年1月7日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 105
- 试验地点
- 22
- 主要终点
- in-segment late lumen loss
研究概览
简要总结
The primary objective of this study is to prove the superior performance of the Ranger™ paclitaxel-coated PTA balloon catheter for angioplasty for femoropopliteal artery lesions when compared to non-coated balloons at six months post-procedure when comparing Late Lumen Loss (LLL). Study statistical hypothesis: The %-mean loss of luminal diameter as assessed by angiography at six months follow-up after treatment of the femoropopliteal artery with Ranger DCB study devices is lower than the %-mean loss of luminal diameter after treatment with uncoated PTA balloon control devices.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects must be age 18 or older
- •Subject is willing and able to provide informed consent
- •Subject is available to attend all required follow-up visits
- •Subject has a clinically significant symptomatic leg ischemia requiring treatment
- •Subject has a Rutherford clinical category of 2-4
- •If the index lesion is restenotic, the prior PTA must have been >30 days prior to treatment in the current study
- •Only one lesion per limb can be treated under this protocol.
- •Successful intraluminal wire crossing of the target lesion
- •Index lesion is a clinically and hemodynamically significant stenotic or restenotic lesion located in the native nonstented superficial femoral artery or proximal popliteal artery
- •Degree of stenosis 70% or more, by visual assessment
- •Lesion length between 20 mm and 150 mm
- •At least one patent infrapopliteal artery to the foot of the index limb
排除标准
- •Subjects who have undergone prior vascular surgery of the femoropopliteal artery in the index limb to treat atherosclerotic disease
- •History of major amputation in the same limb as the target lesion
- •Presence of aneurysm in the target vessel
- •Acute ischemia and/or acute thrombosis in any artery of the lower limbs
- •Acute Myocardial Infarction within 30 days before the index procedure
- •Persistent, intraluminal thrombus of the proposed target lesion post-thrombolytic therapy
- •Known hypersensitivity or contraindication to contrast dye that cannot be adequately pre-medicated
- •Known allergies against Paclitaxel or other components of the used medical devices
- •Intolerance to antiplatelet, anticoagulant, or thrombolytic medications that would be administered during the trial
- •Platelet count <100,000 mm3 or >600,000 mm3
- •Concomitant renal failure with a serum creatinine >2.0 mg/dL
- •Receiving dialysis or immunosuppressant therapy
- •Life expectancy of less than one year
- •Women of child-bearing potential must agree to use a reliable method of contraception from the time of screening through 12 months after the index procedure.
- •Woman who is pregnant or nursing.
- •Previously planned stenting of the index lesion
- •Use of adjunctive therapies (debulking, laser, cryoplasty, re-entry devices)
- •Planned or expected procedures (cardiac, aorta, peripheral) within 30 days after the index procedure
- •Presence of outflow lesions requiring intervention within 30 days of the index procedure
- •Perforated vessel as evidenced by extravasation of contrast media
- •Heavily calcified target lesions resistant to PTA
- •Current participation in another drug or device trial that has not completed the primary endpoint, that may potentially confound the results of this trial, or that would limit the subject's compliance with the follow-up requirements
- •Current participation in any study using drug-coated/drug-eluting technologies
- •Current participation in any study using drug-coated/drug-eluting technologies
- •Target lesion with in-stent restenosis (any stent or stent-graft)
结局指标
主要结局
in-segment late lumen loss
时间窗: six months
In-segment late lumen loss (LLL) of the treated segment after PTA using the Ranger™ paclitaxel-coated PTA balloon, in comparison to the LLL after PTA using an uncoated balloon, as observed by angiography at six months post-index procedure.
次要结局
- procedural success(within 24 hours of index procedure)
- assisted primary patency(twelve months)
- secondary patency(twelve months)
- primary patency(twelve months)
- clinical success(twelve months)
- hemodynamic success(twelve months)
- technical success(during index procedure, less 1 hour)
- binary restenosis rate(twelve months)
- change in quality of life(36 months)
研究者
研究点 (22)
Loading locations...
相似试验
已完成
不适用
Comparison of Agent™ and SeQuent® Please Paclitaxel Coated Balloon Catheters in Coronary In-stent Restenosis (AGENT-ISR)Coronary RestenosisCoronary AtherosclerosisCoronary ArteriosclerosisCoronary Artery DiseaseNCT02151812Hemoteq AG123
招募中
3 期
Study of Paclitaxel Plus Cisplatin as the First-line Chemotherapy in High Risk Gestational Trophoblastic TumorGestational Trophoblastic NeoplasmsNCT02639650Weiguo Lv214
已完成
不适用
Effectiveness of Paclitaxel-coated Luminor® Balloon Catheter Versus Uncoated Balloon Catheter in the Arteria Femoralis SuperficialisPeripheral Arterial DiseaseNCT02540018Jena University Hospital172
已完成
不适用
Compare the Safety and Efficacy of Genoss® DCB and SeQuent® Please NEO in Korean Patients With Coronary De Novo LesionsCoronary Artery DiseaseNCT05096442Genoss Co., Ltd.204
已完成
不适用
Compare the Efficacy and Safety of RESTORE DEB and SeQuent® Please in Chinese Patient With Coronary In-stent RestenosisCoronary RestenosisNCT02944890ZhuHai Cardionovum Medical Device Co., Ltd.242